Clinical Trial

Comparison of Ultrasound Cerebral Perfusion Imaging With Routine Perfusion CT

Study acronym: SCULPT
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 7, 2026 (before its estimated June 4, 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary goal of neurocritical care is to prevent secondary brain injury, which worsens neurological outcomes. Because clinical monitoring is often insufficient due to the patient's condition and medical treatments, multimodal monitoring using biophysical, electrophysiological, and imaging data is essential. In patients with subarachnoid hemorrhage (SAH), the most frequent and severe complication is delayed cerebral ischemia, often linked to arterial vasospasm and potentially leading to infarction. Early diagnosis combines transcranial Doppler (TCD), sensitive to vasospasm, with perfusion CT (CTP), which measures cerebral perfusion; this approach guides therapy and improves prognosis. Ultrasound, especially when enhanced with contrast agents (CEUS), allows non-invasive, bedside, repeated visualization of cerebral blood flow and perfusion-even through the skull. Agents like SonoVue® help quantify perfusion using time-intensity curves. The study aims to assess whether cerebral perfusion measurements from the SYLVER device are equivalent to those from CTP in ICU or CCU patients.
Trial Details
NCT Number NCT07324421
Lead Sponsor Resolve Stroke
Conditions Neuro ICU, Sub Arachnoid Hemorrhage, Neurological Complication, Cerebral Ischemia, Brain Injuries, Vascular
Enrollment 50 participants
Start Date 2025-10-25
Primary Completion 2026-06-04 (estimated)
Study Completion 2026-08-15 (estimated)
Updated on ClinicalTrials.gov 2026-01-07